CLINICAL EFFECTIVENESS OF FIXED DOSE COMBINATION OF EMPAGLIFLOZIN AND LINAGLIPTIN (EMPA/LINA) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS UNWILLING TO CONTINUE BASAL INSULIN THERAPY: A REAL-WORLD EXPERIENCE IN INDIAN SETTING

Mapping Intimacies ◽

10.36106/ijar/7601504 ◽

2021 ◽

pp. 42-44

Author(s):

Supratik Bhattacharyya ◽

Aditya Bikram Mishra ◽

Maneesha Khalse

Keyword(s):

Insulin Therapy ◽

Disease Duration ◽

Clinical Effectiveness ◽

Fixed Dose ◽

Baseline Hba1c ◽

Glycemic Status ◽

Retrospective Assessment ◽

Dose Combination ◽

Indian Setting

Many T2DM patients are reluctant to continue injectable insulin therapy affecting medication adherence. The objective was to investigate the clinical effectiveness with empagliozin/linagliptin (EMPA/LINA) combination in patients unwilling to continue insulin therapy. In this retrospective assessment, a total of 60 patients [(41 men, 19 women); age (± S.D.) 53.38 ± 8.49 years and disease duration 5.67±1.89 years; baseline HbA1c: 7.1±0.58%; BMI: 28.25±4.07 kg/m2 were initiated with EMPA/LINA (25/5 mg) after thorough assessment. During 12-week period, there was modest improvements in glycemic prole [baseline vs. endpoint; HbA1c: 7.1±0.58% versus 7.1±0.55% (p < 0.63), FPG 129±14 mg/dl versus 125±9.3 mg/dl, PPG 154±18 mg/dl versus 143±11 mg/dl (p=0.01), proportion of patients achieving A1C goal with no major hypoglycemia was improved from 37% to 81.48%. The incidence of overall hypoglycemia was reduced. These ndings suggest that patients with stable glycemic status reluctant to continue insulin may have effective transition to EMPA/LINA therapy

Download Full-text

A comparison study on efficacy, insulin sensitivity and safety of Glimepiride/Metformin fixed dose combination versus glimepiride single therapy on type 2 diabetes mellitus patients with basal insulin therapy

Diabetes Research and Clinical Practice ◽

10.1016/j.diabres.2019.107796 ◽

2019 ◽

Vol 155 ◽

pp. 107796 ◽

Cited By ~ 1

Author(s):

Hea Min Yu ◽

Sang Jin Kim ◽

Sung Wan Chun ◽

Keun Young Park ◽

Dong Mee Lim ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Insulin Sensitivity ◽

Insulin Therapy ◽

Basal Insulin ◽

Fixed Dose ◽

Comparison Study ◽

Dose Combination

Download Full-text

Rationality, Efficacy, Tolerability of Empagliflozin plus Linagliptin Combination for the Management of Type 2 Diabetes Mellitus: A Systematic review of randomized controlled trials and observational studies.

Current Diabetes Reviews ◽

10.2174/1573399817666210910165402 ◽

2021 ◽

Vol 17 ◽

Author(s):

Santenna Chenchul ◽

Shoban Babu Varthya ◽

Padmavathi R.

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Clinical Studies ◽

Fixed Dose ◽

Controlled Trials ◽

Baseline Hba1c ◽

Randomized Controlled ◽

Dose Combination ◽

The Mean

Background: Treatment of diabetes mellitus includes more than one drug of different groups, which may lead to high pill burden and non-adherence to drugs. We have aimed to systematically analyze the clinical efficacy, safety and pharmacoeconomic cost-effectiveness of the fixed-dose combination of empagliflozin plus a linagliptin in Type-2 Diabetes mellitus (T2DM) patients. Methods: A literature search of PubMed/MEDLINE, SCOPUS, Google Scholar and EMBASE was performed using the MeSH terms and/or keywords“((Single-pill combination) OR ((Fixed-dose combination) OR (Combination therapy)) AND (Empagliflozin add on-to Linagliptin) OR (Empagliflozin combined with Linagliptin) OR ((Combination of Empagliflozin and Linagliptin)” from the inception to February2021. Results: Search results were found a total of 13 clinical studies. After removing duplicates and studies not according to inclusion criteria a total of eight clinical studies (Randomized controlled trials: 7; Observational cohort studies: 1) were included (n=7491). A significant reduction in the primary endpoint, the mean changes in baseline HbA1c at the end of 24 weeks and/or 52 weeks of the was found in the empagliflozin plus a linagliptin combination group in all included studies. In addition, significant efficacy was seen in decreasing the secondary endpoints such as, the mean change in the fasting plasma glucose, systolic and diastolic blood pressure (DBP) and body weight with less number of adverse events than the adverse effects with either drug alone. Conclusion: After reviewing findings from the available clinical studies of the combination of empagliflozin plus linagliptin we conclude that, the combination is effective, safe, tolerable and rationale cost effective combination compared to placebo and either drug alone for the management of T2DM in patients with inadequate glycemic control with metformin alone, patients with intoleratance to metformin, increased baseline HbA1c, patients with overweight or obesity and diabetic hypertensive, CHF, atherosclerotic cardiovascular disease and renal dysfunction patients. We suggest for more number of future randomized controlled studies in more number of T2DM patients with or without CHF and renal failure patients.

Download Full-text